Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC trimmed its position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 7.9% in the third quarter, Holdings Channel reports. The firm owned 568,517 shares of the biopharmaceutical company’s stock after selling 48,878 shares during the quarter. Geode Capital Management LLC’s holdings in Marinus Pharmaceuticals were worth $1,001,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Suvretta Capital Management LLC boosted its stake in Marinus Pharmaceuticals by 32.8% in the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after acquiring an additional 1,253,901 shares during the period. abrdn plc boosted its stake in Marinus Pharmaceuticals by 146.1% in the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after acquiring an additional 1,578,329 shares during the period. GSA Capital Partners LLP boosted its stake in Marinus Pharmaceuticals by 409.4% in the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock valued at $1,789,000 after acquiring an additional 817,050 shares during the period. Acadian Asset Management LLC acquired a new position in Marinus Pharmaceuticals in the second quarter valued at approximately $813,000. Finally, Renaissance Technologies LLC acquired a new position in Marinus Pharmaceuticals in the second quarter valued at approximately $727,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on MRNS. Royal Bank of Canada decreased their target price on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research note on Friday, October 25th. Truist Financial downgraded Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ:MRNS opened at $0.54 on Friday. Marinus Pharmaceuticals, Inc. has a 12 month low of $0.22 and a 12 month high of $10.50. The stock has a market cap of $29.63 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. The stock’s 50 day moving average price is $0.35 and its 200 day moving average price is $1.02.

Marinus Pharmaceuticals Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.